Neumora Therapeutics (NASDAQ:NMRA) Given “Sector Perform” Rating at Royal Bank of Canada

Royal Bank of Canada reiterated their sector perform rating on shares of Neumora Therapeutics (NASDAQ:NMRA) in a research note released on Tuesday,Benzinga reports. They currently have a $4.00 price target on the stock.

Other equities research analysts have also issued research reports about the company. HC Wainwright dropped their price objective on Neumora Therapeutics from $30.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday. JPMorgan Chase & Co. lowered Neumora Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $18.00 to $15.00 in a research note on Tuesday, November 5th. Bank of America dropped their price objective on Neumora Therapeutics from $22.00 to $7.00 and set a “buy” rating for the company in a research note on Monday, January 6th. William Blair reissued an “outperform” rating on shares of Neumora Therapeutics in a research note on Wednesday, January 15th. Finally, Needham & Company LLC reissued a “buy” rating and set a $5.00 price objective on shares of Neumora Therapeutics in a research note on Tuesday. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $11.50.

Neumora Therapeutics Stock Performance

Shares of NASDAQ NMRA opened at $1.41 on Tuesday. The stock has a market cap of $227.80 million, a PE ratio of -0.75 and a beta of 2.50. Neumora Therapeutics has a fifty-two week low of $1.35 and a fifty-two week high of $21.00. The stock has a fifty day moving average of $3.02 and a 200-day moving average of $8.81.

Neumora Therapeutics (NASDAQ:NMRA) last announced its quarterly earnings results on Thursday, March 6th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.09. On average, sell-side analysts predict that Neumora Therapeutics will post -1.61 EPS for the current year.

Institutional Investors Weigh In On Neumora Therapeutics

Several hedge funds have recently added to or reduced their stakes in NMRA. Mirae Asset Global Investments Co. Ltd. bought a new stake in Neumora Therapeutics during the fourth quarter worth about $61,000. PNC Financial Services Group Inc. bought a new stake in shares of Neumora Therapeutics in the 4th quarter valued at about $64,000. Quantbot Technologies LP bought a new stake in shares of Neumora Therapeutics in the 4th quarter valued at about $92,000. PEAK6 LLC bought a new stake in shares of Neumora Therapeutics in the 4th quarter valued at about $117,000. Finally, EntryPoint Capital LLC bought a new stake in shares of Neumora Therapeutics in the 4th quarter valued at about $135,000. Institutional investors own 47.65% of the company’s stock.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.